Projekt

Selective S1P1 receptor agonist in Patients with Relapsing-Remitting Multiple Sclerosis

Abgeschlossen · 2009 bis 2010

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2009
Ende
2010
Finanzierungsart
Industrie
Studiendesign
Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIb study
Schlagwörter (Tags)
MS, S1P1 receptor agonist, phase II
Webseite
Kurzbeschreibung/Zielsetzung

Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIb study to evaluate the efficacy, safety, and tolerability of three doses of an oral S1P1 receptor agonist, administered for twenty-four weks in patients with relapsing-remitting multiple sclerosis

Primary Outcome meassures:
culmulative number of new gadolinium lesions T1-weighted MRI at weeks 12/16/20/24

Secondary objectives:
- annualized confirmed relapse rate
- time to first confirmed relapse
- safety and tolarability